PathAI logo

Mike Montalto, PhD

Chief Scientific Officer
Mike Montalto, PhD

Connect with Mike


Mike Montalto of PathAI has experience developing digital pathology diagnostic products and driving cutting-edge translational research in a large biopharmaceutical setting. Mike joined PathAI in November 2019 to use AI-powered pathology to support the development of new therapies and diagnostics for patients.

Prior to joining PathAI, Mike led the majority of clinical biomarker central laboratories in Translational Medicine at Bristol-Myers Squibb including translational and digital pathology, immunohistochemistry, clinical genomics, clinical flow cytometry, pre-clinical and clinical non-invasive imaging, biorepository and clinical biomarker sample operations in support of all therapeutic areas for global clinical trials, precision medicine, and companion diagnostics development. Prior to BMS, Montalto was a co-founder and executive of Omnyx, LLC, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products. Prior to this, Montalto was the Molecular Imaging and Diagnostics Advanced Technology Leader at General Electric, where he was a lead inventor of MultiOmyx™, a proprietary pathology-based multiplexing technology for biomarker discovery.

Throughout his career, Mike had a passion for advancing imaging technologies toward unmet scientific and medical needs in a commercial setting to be able to impact patients.

Mike has served as a member of NIH study sections for in vivo molecular imaging centers, designed and led global clinical trials for the registration of digital pathology devices and served as a board member and president of the Digital Pathology Association (DPA). Under his leadership, the DPA successfully collaborated with the FDA to establish industry wide regulatory guidance and clinical trial designs for the clinical use of digital pathology devices. He currently serves on the DPA executive committee as immediate past-president, and on the DPA Foundation’s board of directors. Dr. Montalto earned his PhD in tumor biology from Albany Medical College and received his post-doctoral training in anti-inflammatory drug discovery and whole animal physiology at Brigham and Women’s Hospital, Harvard Medical School.

Leadership Team

Get In Touch

Interested in learning more about PathAI?
Contact Us
Group of Path AI employees working together in a conference room with their laptops